^
BIOMARKER:

BCL2 mutation

i
Other names: BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
Entrez ID:
BCL2 mutation
Follicular Lymphoma
nivolumab + ibrutinib
Sensitive: C3 – Early Trials
BCL2 mutation
Diffuse Large B Cell Lymphoma
ibrutinib
Sensitive: C3 – Early Trials
BCL2 mutation
AML
venetoclax
Sensitive: C3 – Early Trials
BCL2 mutation
Multiple Myeloma
venetoclax
Resistant: C3 – Early Trials
BCL2 mutation
CLL
venetoclax
Resistant: D – Preclinical